Feedback / Questions
HCR-188 - Helicore Biopharma
https://www.globenewswire.com/news-release/2025/03/25/3048810/0/en/Helicore-Biopharma-Announces-First-Participant-Dosed-in-Phase-1-Clinical-Trial-of-HCR-188-a-First-in-Class-GIP-Antagonist-for-the-Treatment-of-Obesity.html
Mar 25, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next